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Background. Hepatitis C virus (HCV) infection has a growing impact on morbidity and mortality in patients
infected with human immunodeﬁciency virus (HIV). We assessed trends in HCV incidence in the different HIV
transmission groups in the Swiss HIV Cohort Study (SHCS).
Methods. HCV infection incidence was assessed from 1998, when routine serial HCV screening was intro-
duced in the SHCS, until 2011. All HCV-seronegative patients with at least 1 follow-up serology were included.
Incidence rates (IRs) of HCV infections were compared between men who have sex with men (MSM), injection
drug users (IDU), and heterosexuals (HET).
Results. HCV incidence was assessed in 3333 MSM, 123 IDU, and 3078 HET with a negative HCV serology
at baseline. Over 23 707 person-years (py) for MSM, 733 py for IDU, and 20 752 py for HET, 101 (3%), 41 (33%),
and 25 (1%) of patients seroconverted, respectively. The IR of HCV infections in MSM increased from 0.23 (95%
credible interval [CrI], .08–.54) per 100 py in 1998 to 4.09 (95% CrI, 2.57–6.18) in 2011. The IR decreased in IDU
and remained <1 per 100 py in HET. In MSM, history of inconsistent condom use (adjusted hazard ratio [HR],
2.09; 95% CI, 1.33–3.29) and past syphilis (adjusted HR, 2.11; 95% conﬁdence interval [CI], 1.39–3.20) predicted
HCV seroconversion.
Conclusions. In the SHCS, HCV infection incidence decreased in IDU, remained stable in HET, and increased
18-fold in MSM in the last 13 years. These observations underscore the need for improved HCV surveillance and
prevention among HIV-infected MSM.
Hepatitis C virus (HCV) infection is a major cause of
morbidity and mortality in patients infected with
human immunodeﬁciency virus (HIV) [1–3]. For
many years, HCV infections occurred almost exclu-
sively in injection drug users (IDU) or hemophiliacs.
In a previous analysis in the Swiss HIV Cohort Study
(SHCS), HCV seroprevalence was 33% overall and
90% among IDU [4]. Recently, there have been several
outbreaks of HCV infections among HIV-infected men
who have sex with men (MSM), predominantly in large
cities in Europe, Australia, and the United States [5–14].
These clusters of HCV infections involved high-risk
sexual behaviors within conﬁned social networks.
However, the impact of these localized epidemics on
the incidence of HCV infections in general HIV-infect-
ed populations and the long-term trends in HCV inci-
dence rates among different transmission risk groups
are largely unknown. A better understanding of
changes in HCV incidence rates and transmission pat-
terns is urgent because of the increasing burden of
HCV-related disease in HIV-infected patients [1–3].
The SHCS offers an ideal platform for studying
changes in HCV incidence in a general HIV-infected
population and in diverse HIV-transmission risk
groups, as all HCV-seronegative patients are screened
routinely at baseline and during follow-up over the
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past 13 years. Furthermore, it allows a thorough evaluation of
the association of HCV seroconversions with different risk
factors, as detailed patient history and clinical data are collect-
ed every 6 months.
We assessed changes in the HCV infection incidence in the
3 main HIV transmission groups (IDU, MSM, and heterosex-
uals [HET]) in the SHCS during the last 13 years, with the
expectation that our results would shed light on the magni-
tude and changes of the HCV epidemic in a general and rep-
resentative HIV-infected population.
METHODS
Swiss HIV Cohort Study
The SHCS (www.shcs.ch) is a prospective cohort study with
ongoing enrollment of HIV-infected adults in Switzerland
since 1988. It covers at least 45% of the cumulative number of
HIV infections declared to the Swiss public health authorities,
69% of all patients living with AIDS, and 75% of patients re-
ceiving antiretroviral therapy (ART) in Switzerland [15]. Rep-
resentativity has remained stable over the years. Detailed
information on demographics, mode of HIV acquisition, risk
behavior, clinical events, coinfections, and treatment is collect-
ed using a standard protocol at registration and at intervals of
6 months. Local ethical committees of all participating study
sites have approved the study and written consent is obtained
from all participants.
Inclusion Criteria and Deﬁnitions
To compare HCV incidence between risk groups, we catego-
rized patients as IDU, MSM, or HET according to the most
probable HIV transmission mode. In order to minimize erro-
neous classiﬁcations, we excluded MSM and HET patients
who reported the use of injection drugs at any occasion
during follow-up. Since 1998, all SHCS patients have been
routinely screened for HCV infection; serology is performed
every second year of follow-up, independent of HIV transmis-
sion mode. Thus, all HCV-seronegative patients who had at
least 1 follow-up HCV antibody measurement after July 1998
were included in the analyses. Positive results by third-genera-
tion enzyme-linked immunosorbent assay (ELISA) were con-
ﬁrmed by immunoblotting. Patients with a positive HCV
serology at entry and those who seroconverted before 1998
were excluded. Individual follow-up ended at the time of the
ﬁrst positive or last negative HCV serology. A detailed patient
ﬂowchart is shown in Figure 1. Previous syphilis was deﬁned
as a positive Treponema pallidum hemagglutination assay
screening test and hepatitis B virus (HBV) exposure as deter-
mined by the presence of a positive anti–hepatitis B core anti-
body test prior to HCV seroconversion, or before the last
negative HCV serology in those without HCV seroconversion.
In this context, the term “HBV exposure” refers to both re-
solved and chronic HBV infections.
A subset of HCV seroconverters was found to have a
unique positive HCV serology followed by ≥1 negative
Figure 1. Study ﬂowchart. Abbreviations: FUP, follow-up; HCV, hepatitis C virus; HET, heterosexual; IDU, injection drug user; IVD, intravenous drugs;
MSM, men who have sex with men; N/A, not applicable; SHCS, Swiss HIV Cohort Study.
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serology. These patients could have cleared HCV antibodies
after spontaneous HCV clearance, as described previously
[16–18]. Alternatively, false-positive results cannot be excluded
despite conﬁrmation by HCV immunoblot. Therefore, the
main analyses were repeated after exclusion of these cases.
Statistical Analyses
HCV incidence rates were assessed from introduction of
routine HCV screening from July 1998 until November 2011.
Patients were considered to be at risk for HCV infection since
the date of their ﬁrst negative HCV serology or since 1 July
1998 if the ﬁrst measurement preceded this date. Individual
follow-up ended at the time of the ﬁrst positive or last negative
HCV serology. Baseline characteristics were compared
between the 3 risk groups using analysis of variance and χ2
tests for continuous and categorical variables, respectively. To
calculate the incidence of HCV infections in the different risk
groups, events were right-censored so that the date of serocon-
version corresponded to the date of the ﬁrst positive HCV se-
rology. Yearly HCV infection incidence rates (IRs) were
obtained using Bayesian Poisson regression models with non-
parametric smoothing priors [19]. Incidence rates are reported
as number of cases per 100 person-years (py) and shown on a
log-scaled graph, by transmission group (ie, MSM, IDU,
HET).
In sensitivity analyses, the yearly rates of HCV infection in
MSM were compared with the results obtained using 2 alter-
nate censoring approaches: (1) midpoint censoring, in which
the date of seroconversion was set to the midpoint between
the last negative and ﬁrst positive HCV serology, and (2) a
nonparametric maximum likelihood estimation method for
interval-censored data [20]. Interval censoring takes into
account that the exact date of seroconversion is not known
but lies between the last negative and the ﬁrst positive serol-
ogy. However, because of the low number of seroconversions
in IDU and HET, this method could only be applied to the
MSM risk group.
Demographic characteristics of HCV seroconverters in
MSM were compared to those who did not seroconvert during
follow-up using χ2 and Mann-Whitney tests. The difference in
incidence of HCV infection between patients of different age
groups, condom use patterns, HBV exposure status, and
history of past syphilis were also shown in log-scaled graphs.
Risk factors for HCV infection in MSM were evaluated using
a multivariate Cox regression model. Analyses were adjusted
for age category (16–29, 30–39, and ≥40 years), CD4 count
category before last HCV serology (<200, 200–499, and ≥500
cells/µL), education level (no, basic, and high-level profession-
al education), region of SHCS follow-up (Zurich or other),
ethnicity (Caucasian or other), use of noninjection drugs (yes
or no), sexual relationships (stable or occasional partners),
condom use (always or inconsistent), past history of syphilis
(yes or no), HBV exposure (yes or no), and ART status (yes
or no). All statistical analyses were performed using Stata 12
software (Stata Corp, College Station, Texas) and the R
package, version 2.14.1 [21] using add-on packages INLA [22]
and Icens [23].
RESULTS
Baseline Characteristics
Of 4629 MSM, 2678 IDU, and 4530 HET screened for HCV
infection, 147 (3.2%), 2468 (92.2%), and 513 (11.3%), respec-
tively, had a positive HCV serology at baseline (Figure 1). A
total of 6534 patients, of whom 3333 were MSM, 123 IDU,
and 3078 HET, were included in the HCV incidence analyses.
Median age at ﬁrst HCV screening test was slightly higher in
MSM (38 years; interquartile range [IQR], 32–44) and HET
(36 years; IQR, 30–44), compared to IDU (33 years; IQR, 28–
40), whereas MSM were more likely to have a high-level edu-
cation than patients in the 2 other groups (Table 1). Almost
half of the MSM and IDU, but only 29% of HET, had their
regular medical follow-up in Zurich, Switzerland’s largest
urban center. Finally, HET were much more likely to be non-
Caucasians (40.7%), compared with MSM (7.7%) and IDU
(8.9%).
HCV Incidence
Over a total follow-up period of 23 707 py for the MSM
group, 733 py for the IDU group, and 20 752 py for the HET
group, 101 (3.0%), 41 (33.3%), and 25 (0.8%) patients, respec-
tively, experienced an HCV seroconversion during follow-up.
Between 1998 and 2011, the IR of HCV infections in MSM
increased from 0.23 (95% credible interval [CrI], .08–.54) per
100 py to 4.09 (95% CrI, 2.57–6.18) in 2011, with 51 cases
observed in the last 3 years (Figure 2). There was a similar
increase in patients followed in Zurich compared with those
in the rest of the country (in 2011, IRs were 2.61 [95% CrI,
1.19–5.13] and 4.10 [95% CrI, 2.18–7.16] per 100 py, respec-
tively). Increases in HCV incidence in MSM were similar
when right censoring, midpoint censoring, or interval censor-
ing was used to estimate yearly incidence rates (Supplementa-
ry Figure 1).
In IDU, the HCV infection IR decreased from 13.89 (95%
CrI, 8.20–22.39) per 100 py in 1998 to 2.24 (95% CrI, .55–
10.66) in 2011, with only 3 incident cases in the last 3 years.
For comparison, the yearly IR of HCV infections in the HET
group remained <0.5 per 100 py, with only 2 cases in 2011
(IR, 0.43 per 100 py [95% CrI, .12–1.29]; Figure 2).
Twenty-ﬁve (15.0%) HCV seroconverters had a unique pos-
itive serology followed by negative tests. Of those, 6 patients
had their HCV infection conﬁrmed by HCV RNA testing
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within 1 month of the positive serology. In another 8 patients,
HCV RNA testing was negative, which may be reﬂective of
spontaneous HCV clearance and loss of HCV antibodies over
time. Eleven patients did not have HCV RNA results available
to conﬁrm the HCV infection. After exclusion of these pa-
tients, the incidence rates of HCV infection remained similar
to the results described above (1998: MSM: IR, 0.11 per 100
py [95% CrI, .03–.35]; IDU: IR, 14.36 [95% CrI, 8.36–23.39];
Table 1. Baseline Characteristics of Patients Included in Incidence Analyses
Characteristic MSM IDU HET Total
No. of patients 3333 123 3078 6534
Sex
Male 3333 (100) 76 (61.8) 1339 (43.5) 4748 (72.7)
Female 0 47 (38.2) 1739 (56.5) 1786 (27.3)
Median age (IQR) at first HCV serology 38 (32–44) 33 (28–40) 36 (30–44) 37 (31–44)
Region of SHCS follow-up
Outside Zurich 1759 (52.8) 71 (57.7) 2184 (71.0) 4014 (61.4)
Zurich 1574 (47.2) 52 (42.3) 894 (29.0) 2520 (38.6)
Education level
No prof. education 76 (2.3) 10 (8.9) 348 (11.6) 434 (6.8)
Basic prof. education 1816 (56.1) 90 (80.4) 1979 (65.9) 3885 (61.1)
High-level education 1348 (41.6) 12 (10.7) 676 (22.5) 2036 (32.1)
Ethnicity
Caucasian 3075 (92.3) 112 (91.1) 1825 (59.3) 5012 (76.7)
Non-Caucasian 258 (7.7) 11 (8.9) 1253 (40.7) 1522 (23.3)
All data are No. (%) unless otherwise specified. Comparison of characteristics between 3 risk groups: P < .001 for all variables.
Abbreviations: HCV, hepatitis C virus; HET, heterosexual; IDU, injection drug user; IQR, interquartile range; MSM, men who have sex with men; prof.,
professional; SHCS, Swiss HIV Cohort Study.
Figure 2. Hepatitis C virus infection incidence rates by transmission group (shaded: 95% credible intervals). Abbreviations: HET, heterosexual; IDU, injection
drug user; MSM, men who have sex with men; py, person-year.
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HET: IR, 0.09 [95% CrI, .02–.35]; 2011: MSM: IR, 3.56 [95%
CrI, 2.19–5.53]; IDU: IR, 2.42 [95% CrI, .51–13.36]; HET: IR,
0.47 [95% CrI, .14–1.30]).
Predictors of HCV Infection in MSM
Most demographic and behavioral characteristics were similar
in HCV seroconverters compared with patients who did not
seroconvert (Supplementary Table 1). Median age was 34.9
years in seroconverters and 37.7 years in nonseroconverters,
and the proportion of Caucasians was 93% and 92%, respec-
tively. In both groups, >90% of patients started ART before or
during follow-up. However, previous HBV exposure, a past
history of syphilis, and inconsistent condom use were more
common in HCV seroconverters (Supplementary Table 1).
The incidence of HCV infection was higher in patients
who reported inconsistent condom use, as well as in those
who had a previous episode of syphilis or exposure to HBV
compared with the other patients (Figure 3). In adjusted Cox
regression analyses, only inconsistent condom use (adjusted
hazard ratio [aHR], 2.09 [95% conﬁdence interval {CI}, 1.33–
3.29]) and previous diagnosis of syphilis (aHR, 2.11 [95% CI,
1.39–3.20]) were signiﬁcantly associated with HCV seroconver-
sion (Table 2).
Age, education level, CD4+ T-cell count, ART status, and
the other variables included in the multivariate model were
not signiﬁcantly associated with the main outcome. Of note,
having occasional sexual partners (aHR, 0.97 [95% CI, .56–
1.68]) and being followed up in Zurich (aHR, 1.30 [95% CI,
.87–1.97]) did not predict HCV seroconversion.
Of the 63 (62%) HCV infections in MSM with detectable
HCV RNA and available genotyping results, the majority were
caused by HCV genotype 1 (42 cases [66.7%]), followed by
genotypes 4 (12 cases [19.0%]), 3 (8 cases [12.7%]), and 2 (1
case [1.6%]).
Figure 3. Hepatitis C virus infection incidence by risk factor in men who have sex with men (shaded: 95% credible intervals). Abbreviation: py =
person-year.
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DISCUSSION
We assessed trends in HCV infection incidence between 1998
and 2011 in the main HIV transmission groups in the SHCS.
In a population of >6500 patients screened every 2 years for
HCV infection, we found that the yearly incidence rate had
decreased in IDU, remained stable in HET, and dramatically
increased in MSM. In the latter subpopulation, 50% of all
Table 2. Predictors of Acquisition of Acute Hepatitis C Virus Infection in Men Who Have Sex With Men (Cox Regression Model)
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value Adjusted HR (95% CI) P Value
Age group, years .39 .24
16–29 Ref. Ref.
30–39 .72 (.43–1.21) .71 (.42–1.22)
>39 .71 (.42–1.21) .60 (.33–1.09)
CD4 count, cells/µLa .28 .33
<200 Ref. Ref.
200–499 1.09 (.39–3.03) 1.22 (.43–3.47)
>499 .79 (.28–2.18) .88 (.31–2.54)
HIV RNA, <50 copies/mLa .04 .08
Undetectable Ref. Ref.
Detectable 1.64 (1.04–2.59) 1.63 (.94–2.83)
Education level .91 .71
No prof. education Ref. Ref.
Basic prof. education 1.05 (.26–4.30) 1.24 (.30–5.17)
High-level education 1.14 (.27–4.70) 1.44 (.34–6.13)
Region of SHCS follow-up .28 .20
Outside Zurich Ref. Ref.
Zurich 1.24 (.84–1.84) 1.30 (.87–1.97)
Ethnicity .81 .91
Other Ref. Ref.
Caucasian .91 (.42–1.96) 1.04 (.47–2.31)
Use of noninjection drugs .96 .20
No Ref. Ref.
Yes .99 (.65–1.51) .74 (.47–1.17)
Sexual partnersb .43 .91
None or only stable Ref. Ref.
Occasional partner(s) 1.23 (.74–2.05) .97 (.56–1.68)
Condom useb .001 .002
Always Ref. Ref.
Inconsistently/never 2.03 (1.33–3.10) 2.09 (1.33–3.29)
Past history of syphilis <.001 <.001
No Ref. Ref.
Yes 2.20 (1.48–3.27) 2.11 (1.39–3.20)
HBV exposure .12 .08
No Ref. Ref.
Yes 1.39 (.92–2.09) 1.48 (.95–2.28)
ART statusb .31 .92
No Ref. Ref.
Yes .67 (.31–1.45) 1.05 (.43–2.56)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard
ratio; prof., professional; SHCS, Swiss HIV Cohort Study.
a Last measurement before last negative HCV serology, or first positive serology in seroconverters.
b During follow-up (before last negative test, or first positive test in seroconverters).
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HCV infections occurred in the last 3 years. In MSM, a history
of inconsistent condom use and a past episode of syphilis were
signiﬁcantly associated with HCV seroconversion.
Since 2005, several local reports have described epidemics
of HCV infection among HIV-infected MSM [7–12]. Phyloge-
netic and sociodemographic analyses have shown that these
infections occurred within conﬁned groups of MSM with
high-risk sexual behavior in large urban centers [11, 24].
Therefore, incidence estimates in these cohorts were not repre-
sentative for the general HIV-infected population, in contrast
to our study. The systematic, nationwide screening of all HIV-
infected patients at risk since 1998 allowed us to accurately
estimate the trends in HCV incidence among different risk
groups. Since 1998, the incidence of HCV infection among
MSM has increased 18-fold, reaching 4.1 cases per 100 py in
2011. This incidence was higher compared with the large ma-
jority of previous studies among HIV-infected MSM reporting
estimates lower than 1 case per 100 py [5]. However, the most
recent HCV incidence in the SHCS was similar to estimates
from an international cohort collaboration of HIV sero-
converters, where incidence estimates ranged from 2.3 to 5.1
per 100 py in 2007 [25]. In accordance with previous clusters
of HCV infections in large cities, the HCV incidence increased
markedly among individuals treated in Zurich, the largest
urban center in Switzerland which, to some extent, is compa-
rable to other large cities in Europe and the United States.
However, our study shows that HCV incidence increased simi-
larly outside the Zurich area, indicating a nationwide increase
in HCV infections in HIV-infected MSM.
In line with previous reports [4, 8, 11], unprotected anal sex
was an important risk factor for HCV infection in MSM. In
the SHCS, inconsistent condom use doubled the risk of HCV
infection in MSM. Furthermore, a previous syphilis infection
independently increased the risk of an HCV seroconversion
approximately 2-fold. Of note, we recently observed a signiﬁ-
cant increase in syphilis acquisition among MSM in the
SHCS, paralleling the current HCV epidemic [26]. The shared
route of transmission of the 2 infections is the most likely ex-
planation for this association. Alternatively, it is also conceiv-
able that the mucosal disruption caused by syphilitic ulcers
facilitates HCV infections. These ﬁndings underscore the im-
portance of the link between high-risk sexual behavior and
HCV transmissions. As yearly syphilis screening and baseline
HBV serology testing are routine for all MSM in the SHCS, a
positive test result should be an important warning sign and
lead to intensiﬁed counseling on the prevention of sexually
transmitted HCV infection in these high-risk patients. Our
results support recent guidelines [27] to screen HIV-infected
MSM with high-risk sexual behaviors or concomitant ulcerative
sexually transmitted diseases for HCV, and to screen for syphi-
lis in MSM with acute hepatitis C. Although the use of
noninjection drugs has been associated with HCV infections
among HIV-infected MSM [28], we found no association
between noninjection drug use and HCV seroconversion in
MSM. However, we cannot exclude that our analysis underesti-
mates the effect of noninjection drug use due to underreporting
of this behavior. Neither immunological status nor HIV RNA
was associated with HCV seroconversion: the large majority
(96%) of HCV infections occurred with CD4 T-cell counts
>200 cells/μL, and most patients (93%) were undergoing ART.
The incidence of HCV infection in HIV-infected IDU in the
SHCS has decreased in recent years, underscoring the consider-
able success of preventive interventions such as methadone sub-
stitution and needle exchange programs in reducing HCV
infections in IDU followed in routine HIV care. Furthermore,
Switzerland’s long-term heroin prescription program likely con-
tributed to the decreasing incidence of HCV seroconversion in
this population. Besides a reduction in risk behavior, it is also
possible that protective genetic markers have been enriched
during the course of the epidemic in uninfected IDU, as has
been demonstrated recently [29]. However, the large majority
(90%) of IDU were excluded from the incidence analyses
because they already had a positive HCV serology at entry, lim-
iting the size of the IDU population available for the incidence
calculations. In line with previous studies [30, 31], the incidence
of HCV infection in HET has remained very low, and we
cannot exclude that the few incident cases were related to undis-
closed IDU- and/or MSM-related sexual activity. This is corrob-
orated by recent phylogenetic studies within the SHCS which
revealed that approximately 11% HIV pol sequences from het-
erosexuals were linked to transmission clusters of MSM [32].
The major strength of our study is the long-term routine
HCV screening at baseline and during follow-up in a repre-
sentative, nationwide HIV population and in different trans-
mission groups. Routine serological surveillance of HCV
infection is paramount to the diagnosis of new infections, as
the majority of individuals experiencing such an event remain
asymptomatic and transaminase elevations can be transient
and unrecognized. Furthermore, we could minimize transmis-
sion group misclassiﬁcation through the availability of detailed
longitudinal information on sexual activity and drug abuse.
An important limitation of our analysis is that we could not
estimate the exact HCV seroconversion dates between 2 sero-
logical screening tests. Furthermore, a limited number of pa-
tients might have experienced HCV reinfections, which
cannot be recognized by serological testing, possibly leading to
the underestimation of the true overall incidence of HCV in-
fection. Similarly, the incidence might have been underesti-
mated in patients with late or absent seroconversion, as
described by Thomson et al [13]. A further limitation lies in
the suboptimal sensitivity and speciﬁcity of HCV antibody
assays. Although positive ELISA tests were routinely
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conﬁrmed by immunoblotting, false-positive results cannot be
entirely excluded. Finally, some patients who experienced an
HCV seroconversion could have lost their antibodies within a
few months after the infection in the setting of spontaneous
HCV clearance [16–18]. In the SHCS, 25 seroconverters had a
unique positive HCV serology, followed by further negative
tests. However, incidence rates remained similar after exclud-
ing these patients.
In the SHCS, the large majority of recent HCV infections
occurred in MSM. This underscores the need for improved
HCV surveillance and prevention among HIV-infected MSM.
Accordingly, the intervals of HCV screening were reduced to
1 year in the SHCS. This should allow for earlier identiﬁcation
of patients with new HCV infections in order to optimize
counseling with regard to HCV transmission risks, and to
improve the response to HCV therapy by initiating treatment
during acute infection. The revised screening practice in the
SHCS is in line with recent guidelines, which recommend
yearly screening for all HIV-infected MSM who engage in any
risk behavior [33–35]. Furthermore, a recent study demon-
strated that yearly serological HCV screening and biannual
liver function testing is cost-effective [36]. Importantly, this
analysis demonstrated that the optimal screening strategy
strongly depends on HCV incidence. For instance, it suggests
that screening every 3 months with liver function tests is cost-
effective in settings with HCV incidences >1.25%. According-
ly, our results should provide important information for estab-
lishing cost-effective screening programs in HIV-infected
patients. However, routine serological screening does not
prevent risk behavior, and coordinated efforts between physi-
cians and public health representatives are needed to control
the ongoing HCV infection epidemic in HIV-infected MSM.
Although most reported HCV transmissions among MSM oc-
curred in HIV-infected patients, it is conceivable that HCV
incidence among HIV-negative MSM is underestimated as
these individuals are not in regular medical care. Clinicians
and patients should be aware of the risk of acute HCV infec-
tion in MSM, and intensiﬁed prevention and counseling
should be performed. Despite the fact that ART is highly efﬁ-
cient in preventing HIV transmission, it does not have any
effect on prevention of other sexually transmitted infections.
Condom use has declined in recent years in MSM with sup-
pressed HIV load in the SHCS [37], which likely contributes
to the increasing incidence of HCV infection in this popu-
lation. It is crucial that HIV-infected MSM are counseled
with regard to the risks of sexual activities that involve trau-
matic mucosal sex, and that condoms are used consistently
during high-risk sexual activity [28]. The example of IDUs
demonstrates that it is possible to reduce the incidence of
HCV infections through improved screening and preventive
interventions.
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